AzTrials
AzTrials

HealthyEPACMNCT06755112

Efficacy Processes of Aesthetic and Cosmetic Methods

A study testing active cream in people with Healthy, run by University of West Attica at 1 site in Greece.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Study with biophysical methods and skin biopsies to evaluate the effect on the skin of healthy volunteers of 1. cosmetic creams of Unisooth EG-28® mixture before and after Nd:YAG and 2. the Unisooth EG-28® ingredient with iontophoresis and external application of cosmetic cream with active ingredient Olea vitae PLF®. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Healthy
What is being tested?
active cream
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
45 participants
Where
1 siteGreece
Study dates
8 Jan 2023to 31 Jul 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Volunteer individuals aged 18 to 65 years, either sex
  • Written and informed consent
  • Healthy volunteers without skin disease or any other diseases (acute or chronic)

Who cannot join

  • Pregnancy, lactating, or planned pregnancy
  • People who use external application containing steroids for the treatment of skin disease more than one month
  • Participated in the same trial within six months from the interview
  • People with hypersensitive skin
  • Skin abnormalities such as severe acne, erythema, telangiectasia on the test site
  • Used the same or similar cosmetic (or pharmaceutical) on the test site within three months from the interview
  • Have peeling of skin or wrinkles removed within six months from the interview
  • Other unsuitable reasons for clinical trial based on the discretion of the investigator

Trial locations and contacts

1 site in 1 country.

Greece1 site
  • UNIWA

    Aigáleo, Attica, 14423

Other trials in Greece

About this study

Official title: A Study With Biophysical Methods and Skin Biopsies to Evaluate the Effect on the Skin of Healthy Volunteers of Cosmetic Creams Before and After the Use of Nd:YAG Laser

Study with biophysical methods and skin biopsies to evaluate the effect on the skin of healthy volunteers of

  1. cosmetic creams of Unisooth EG-28® mixture before and after Nd:YAG and
  2. the Unisooth EG-28® ingredient with iontophoresis and external application of cosmetic cream with active ingredient Olea vitae PLF®.

OBJECTIVE: To be investigated by approved non-invasive biophysical methods (Directive 2003/15/EC of the European Parliament and of the Council of 27 February 2003 amending Council Directive 76/768/EEC on the approximation of the laws of the Member States relating to cosmetic products. Official Journal L 066, 11/03/2003 P. 0026 - 0035), such as transdermal water loss, erythema, pigmentation, keratin hydration (MPA 5 device), elasticity (Cutometer 575 device) and skin microtopography-thin line skin surface imaging (Skin Visoscan VC 98 and Skin Visiometer) and by minimally invasive methods such as skin biopsies, the effect on the skin of substances with a) anti-inflammatory action and b) antioxidant-anti-ageing action incorporated in cosmetic products when applied alone and/or in combination with other aesthetic approved methods with or without the use of devices used in Aesthetics such as Laser Nd:YAG, or diode laser, iontophoresis.

Read the detailed description

Background and study aims This study aims to evaluate the effects of certain cosmetic creams on the skin of healthy volunteers. Researchers will use biophysical methods and skin biopsies to assess the impact of these creams, both alone or/and in combination with laser treatments.

The study will include efficacy tests (efficacy tests-claim substantiation) with biophysical methods in healthy volunteers of the above-mentioned bioactive substances incorporated in products when applied on their skin either with topical application or in combination with the use of machinery (iontophoresis) and the comparison of results between the methods used.

Healthy male and female volunteers aged 18 to 65 years can participate in this study. Participants will apply either an active cream or a placebo cream to the inner surface of both arms twice daily (morning and evening) for a certain period. The study will measure transdermal water loss, erythema, pigmentation, and keratin hydration using the MPA 5 device before the beginning of the trial and at the end . Elasticity will be measured using the Cutometer 575 device at the same time points. Additionally, small skin biopsies will be taken before starting the cream application and after 14 days to assess collagen improvement.

The study aims to demonstrate the effectiveness of the active ingredients in the cosmetic formulations. The results will help understand how these ingredients and treatments affect the skin. While the non-invasive tests are safe, the skin biopsies are minimally invasive and carry a small risk of discomfort or minor complications.

Study was conducted at the Established Laboratory of Chemistry - Biochemistry - Cosmetology, Department of Biomedical Sciences, University of West Athens, Aegaleo Alsace Campus (Greece)

Conditions
Healthy
Being tested
Placebo cream, active cream
Keywords
Olea europaea stem cells, epilation, skin biopsies, efficacy, biophysical measurements, skin care, formulation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Placebo creamOther

    Placebo cream application

  • active creamOther

    Active cream application

Study groups in NCT06755112
Study groupRoleWhat they receive
placebo creamPlacebo comparatoreveryday using of placebo cream
Receives: Other: Placebo cream
active creamActive comparatoreveryday using of active cream
Receives: Other: active cream

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Trans epidermal water loss (TEWL)

    Tewameter MPA-5 Courage + Khazaka electronic GmbH (Germany) was used

    Measured: 2 weeks

  2. keratin hydration

    Corneometer CM 825 Courage + Khazaka electronic GmbH (Germany) was used

    Measured: 2 weeks

  3. melanin and skin erythema.

    Mexameter MPA-5 Courage + Khazaka electronic GmbH (Germany) was used

    Measured: 2 weeks

  4. skin elasticity

    Cutometer MPA 580, Courage + Khazaka electronic GmbH (Germany) was used for skin elasticity parameters: R2: visco-elasticity in % (resistance to the mechanical force versus ability of recovery), R5: net elasticity in %: Ur/Ue = elastic part of the suction phase vs. immediate recovery during relaxation phase, R7: Ur/Uf proportion of the immediate recovery compared to the amplitude after suction in %.

    Measured: 2 weeks

  5. Skin Biopsies

    Skin puncture biopsies (2.5-3.0 mm) were taken from the forearm of each volunteer. The samples were taken before treatment (Pre-treatment) D=0 and 14 days after laser and product application (Post treatment) D= 14, to all 12 volun-teers. The skin was cleaned with a providone-iodine solution, before taking the biopsy, and the area was anesthetized with a xylocaine solution with epineph-rine. A special cylindrical tool was used, which was rotated through the skin, to remove a small part of the skin, including deeper layers. The incision depth was up to the dermis. The biopsies were placed in numbered vials with formalin so-lution and then fixed for observation under the optical microscope. The goal was to observe the possible increase in the thickness of the epidermis, or the dermis, as well as the morphological observation of the structure of the dermis, in terms of collagen and elastin fibers. The dermis' thickness was measured from the start of the dermoepidermal synapse to the end o

    Measured: 2 weeks

Secondary outcomes (1)
  1. self assesment questionnaire

    Finally, forty-five female volunteers aged between 18-65 , phototypes II and III, according to Fitzpatrick classification, were included in the self-questionnaire study after the appropriate signed informed consent. The study was conducted during the years 2022-2023. Treated areas with active cream or placebo were left or right arm, randomly assigned .

    Measured: 2 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Jan 2025
  2. Study start8 Jan 2023
  3. Primary completion31 Jul 2023
  4. Study completion31 Jul 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
45 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06755112
Sponsor's protocol ID
37942/11-05-2021
Acronym
EPACM
Status last verified
Dec 2024
First submitted
22 Dec 2024
Last updated
1 Jan 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: University policy

Questions about this trial

What is this clinical trial studying?

A study testing active cream in people with Healthy, run by University of West Attica at 1 site in Greece.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Trans epidermal water loss (TEWL) (time frame: 2 weeks). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jan 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in